These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30254313)

  • 21. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
    Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
    BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
    Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
    BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
    Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
    Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
    Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
    Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area.
    Comar M; Zanotta N; Bonotti A; Tognon M; Negro C; Cristaudo A; Bovenzi M
    PLoS One; 2014; 9(8):e104848. PubMed ID: 25162674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATG5 as biomarker for early detection of malignant mesothelioma.
    Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
    BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.
    Weber DG; Brik A; Casjens S; Burek K; Lehnert M; Pesch B; Taeger D; Brüning T; Johnen G;
    BMC Res Notes; 2019 Feb; 12(1):77. PubMed ID: 30744695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
    Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR
    Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA
    BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
    Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A recombinant polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma.
    Raiko I; Rihs HP; Gleichenhagen J; Sander I; Kollmeier J; Lehnert M; Brüning T; Johnen G
    Biochem Biophys Res Commun; 2017 Apr; 486(2):526-532. PubMed ID: 28322788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.
    Linch M; Gennatas S; Kazikin S; Iqbal J; Gunapala R; Priest K; Severn J; Norton A; Ayite B; Bhosle J; O'Brien M; Popat S
    BMC Cancer; 2014 Sep; 14():674. PubMed ID: 25227779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant Mesothelioma of Spermatic Cord in an Elderly Man With a History of Asbestos Exposure.
    D'Antonio A; Mastella F; Colucci A; Silvestre G
    Urology; 2016 Jan; 87():e1-3. PubMed ID: 26433083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    Tsim S; Alexander L; Kelly C; Shaw A; Hinsley S; Clark S; Evison M; Holme J; Cameron EJ; Sharma D; Wright A; Grundy S; Grieve D; Ionescu A; Breen DP; Paramasivam E; Psallidas I; Mukherjee D; Chetty M; Cox G; Hart-Thomas A; Naseer R; Edwards J; Daneshvar C; Panchal R; Munavvar M; Ostroff R; Alexander L; Hall H; Neilson M; Miller C; McCormick C; Thomson F; Chalmers AJ; Maskell NA; Blyth KG
    J Thorac Oncol; 2021 Oct; 16(10):1705-1717. PubMed ID: 34116230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.